Major Depressive Disorder Market Growth is Driven by Rising Mental Health Burden and Innovative Therapies | Pfizer Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd.

The global Major Depressive Disorder Market size reached US$ 6.84 billion in 2024 and is expected to reach US$ 14.57 billion by 2033, growing at a CAGR of 8.8% during the forecast period 2025-2033.

Major Depressive Disorder Market Report by DataM Intelligence offers a detailed assessment of the global pharmaceutical and healthcare landscape, highlighting market size, key players, and critical growth drivers. With a focus on emerging drug technologies, evolving treatment paradigms, and regulatory frameworks, the report delivers strategic insights to support stakeholders in navigating the rapidly advancing sector from 2025 to 2033.

Download exclusive insights with our detailed sample report (Corporate Email ID gets priority access): https://www.datamintelligence.com/download-sample/major-depressive-disorder-market?ophp

Major Depressive Disorder is a common and serious mental illness characterized by persistent feelings of sadness, loss of interest, and functional impairment. The market for MDD is growing steadily due to increasing awareness, improved diagnostics, and a rise in stress-related disorders. The global MDD therapeutics market is expanding with new drug approvals, novel mechanisms of action, and AI-based mental health tools gaining traction.

Major Depressive Disorder Market Competitors Overview:

Pfizer Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Viatris Inc., Sun Pharmaceutical Industries Ltd., Eli Lilly and Company, Otsuka Pharmaceutical Co., Ltd., Aurobindo Pharma Limited, Sanofi, Biogen, among others.

Important Industry Updates of 2023, 2024 and 2025:

☐ Johnson & Johnson announced a $14.6 billion acquisition of Intra-Cellular Therapies to expand its neuroscience pipeline, gaining the MDD drug CAPLYTA and other CNS assets. The deal strengthens J&J's position in the growing market for novel depression treatments.

☐ In January 2025, the FDA approved SPRAVATO (esketamine) as the first monotherapy nasal spray for MDD, a major milestone in fast-acting antidepressant therapies. The approval is expected to boost demand and drive further innovation in NMDA-targeting treatments.

☐ Magstim received FDA clearance in May 2025 for its Horizon Inspire System, a transcranial magnetic stimulation (TMS) device for MDD and related disorders. This expands access to non-invasive neuromodulation treatments for depression.

Methodology and Scope

The Major Depressive Disorder Market Report is built on a rigorous research methodology that integrates primary interviews, expert insights, and validated secondary data from company reports, industry publications, and reliable databases. Utilizing both bottom-up and top-down approaches, the analysis ensures high data accuracy through triangulation. The report covers current market dynamics, growth opportunities, and key strategic developments across global and regional markets.

Speak to Our Analyst and Get Customization in the report as per your requirements: https://www.datamintelligence.com/customize/major-depressive-disorder-market?ophp

Major Depressive Disorder Market Segments Overview:

☐ By Drug Type (Antidepressants, Atypical Antidepressants, Antipsychotics, Neuromodulators)
☐ By Route of Administration (Oral, Intravenous, Parenteral)
☐ By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies)

Regional Overview for Major Depressive Disorder Market:

⇥ North America (U.S., Canada, Mexico)
⇥ Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)
⇥ Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)
⇥ South America (Colombia, Brazil, Argentina, Rest of South America)
⇥ Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

Looking for in-depth insights? Grab the full report: https://www.datamintelligence.com/buy-now-page?report=major-depressive-disorder-market?ophp

The Report Covers:

➡ In-depth analysis of the demand-supply gap, market size estimates, SWOT and PESTEL analysis, along with global market forecasts.
➡ Strategic recommendations with a focused go-to-market approach.
➡ An unbiased evaluation of overall market performance.
➡ Region- and country-specific insights, with customized reports available upon request.
➡ Identification of high-potential and niche segments and regions demonstrating strong growth prospects.

People Also Ask:

➤ What are the current global trends in sales, production, imports, and exports within the «Keyword» market?
➤ Who are the leading manufacturers, and what are their production volumes, pricing strategies, and revenue metrics?
➤ What are the major opportunities and challenges facing vendors in this market?
➤ Which product categories, applications, or end-user segments are contributing most to market growth and share?
➤ What are the primary factors driving and restraining growth in the «Keyword» market?

Unlock 360° Market Intelligence with DataM Subscription Services:
https://www.datamintelligence.com/reports-subscription

✅ Technology Roadmap Analysis
✅ Sustainability Impact Analysis
✅ KOL / Stakeholder Insights
✅ Pipeline Analysis For Drugs Discovery
✅ Positioning, Pricing & Market Access Snapshots
✅ Market Volatility & Emerging Risks Analysis
✅ Competitive Landscape

Have a look at our Subscription Dashboard:
https://www.youtube.com/watch?v=x5oEiqEqTWg

Contact Us -
Company Name: DataM Intelligence
Contact Person: Sai Kiran
Email: Sai.k@datamintelligence.com
Phone: +1 877 441 4866
Website: https://www.datamintelligence.com

About Us -
DataM Intelligence is a Market Research and Consulting firm that provides end-to-end business solutions to organizations from Research to Consulting. We, at DataM Intelligence, leverage our top trademark trends, insights and developments to emancipate swift and astute solutions to clients like you. We encompass a multitude of syndicate reports and customized reports with a robust methodology.
Our research database features countless statistics and in-depth analyses across a wide range of 6300+ reports in 40+ domains creating business solutions for more than 200+ companies across 50+ countries; catering to the key business research needs that influence the growth trajectory of our vast clientele.

This release was published on openPR.